ReviewFrontiers in immunology2026
Clinical impact and therapeutic potential of tertiary lymphoid structures in melanoma.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tertiary lymphoid structures (TLS) are ectopic lymphoid aggregates that arise in non-lymphoid tissues under conditions of chronic inflammation, including cancer. Structurally and functionally resembling secondary lymphoid organs, TLS consist of organized T-cell zones, B-cell follicles, dendritic cells, high endothelial venules, and specialized stromal cells, enabling local antigen presentation and adaptive immune activation. In melanoma, the prototypical immunogenic tumor, the presence of TLS within the tumor microenvironment has been associated with enhanced immune surveillance and favorable clinical outcomes. However, emerging evidence indicates that TLS can also harbor immunosuppressive niches, potentially depending on their developmental stage and cellular composition. In this review, we summarize the molecular and cellular mechanisms underlying TLS biogenesis and outline the experimental methodologies currently used for their identification and characterization, with a focus on melanoma. We examine the clinical relevance of TLS in both primary and metastatic melanomas and discuss strategies aimed at inducing functional TLS within tumors. By promoting TLS formation to amplify intratumoral immune responses, these approaches hold promise for overcoming resistance to immunotherapy and improving outcomes in advanced melanoma and other malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.